The federal government’s scientific advisory infrastructure — built over decades, staffed by thousands of unpaid experts, and relied upon to guide decisions affecting hundreds of millions of Americans — has been taken apart with remarkable speed. Twenty-seven percent of the advisory committees at the Department of Health and Human Services have been eliminated since Robert F. Kennedy Jr. took the helm as secretary. That’s not a trim. That’s an amputation.
According to a detailed investigation by Ars Technica, HHS has dissolved at least 27 of its roughly 100 advisory committees since Kennedy assumed leadership of the department. These weren’t ceremonial bodies that met once a year to rubber-stamp bureaucratic paperwork. They were the panels that evaluated vaccine safety, assessed drug risks, reviewed environmental health threats, and advised on everything from blood supply protocols to dietary guidelines. The committees included experts in epidemiology, toxicology, oncology, pediatrics, and dozens of other specialties — people who donated their time because they believed in the mission of public health.
Now many of those panels simply no longer exist.
The dismantling began almost immediately after Kennedy’s contentious Senate confirmation. One of the earliest casualties was the Advisory Committee on Immunization Practices, or ACIP, the body whose recommendations have for decades determined which vaccines are included in the childhood immunization schedule and covered by insurance. ACIP’s dissolution sent shockwaves through the medical community. Pediatricians, hospital systems, and state health departments had depended on its guidance as a kind of gold standard — a consensus view from credentialed scientists reviewing the best available evidence.
Kennedy’s office framed the cuts as an efficiency measure, part of a broader government streamlining effort aligned with the administration’s DOGE-inspired push to reduce what it calls bureaucratic bloat. In public statements, HHS officials described the advisory committees as outdated, duplicative, and, in some cases, compromised by conflicts of interest with the pharmaceutical industry. Kennedy himself has long argued that federal health agencies have been “captured” by the industries they’re supposed to regulate. It’s a charge that resonates with a segment of the public deeply skeptical of institutional authority. But the specifics of which panels were cut — and what they actually did — tell a more complicated story.
Take the National Vaccine Advisory Committee. Or the Advisory Committee on Blood and Tissue Safety and Availability. Or the Board of Scientific Counselors at the National Institute of Environmental Health Sciences. These weren’t lobbying fronts. They were composed of researchers, clinicians, and public health professionals selected through a formal vetting process and subject to financial disclosure requirements. Their meetings were public. Their recommendations were non-binding. And their collective expertise represented something that can’t be easily replaced by political appointees or contracted consultants: deep, specialized knowledge applied in a deliberative, transparent setting.
The consequences are already materializing. As Ars Technica reported, the elimination of ACIP has created a vacuum in vaccine policy. Without its structured review process, decisions about immunization recommendations now rest more squarely with political leadership at the CDC — leadership that Kennedy has installed. Several states have indicated they may begin developing their own independent advisory mechanisms, a fragmentation that public health officials warn could produce a patchwork of conflicting guidance across the country.
This isn’t hypothetical. It’s happening.
In recent weeks, reports have surfaced of confusion among healthcare providers about updated guidance on measles and RSV vaccines, with some clinicians unsure which recommendations still stand and which have been effectively orphaned by the dissolution of the committees that produced them. The American Academy of Pediatrics has issued statements urging physicians to continue following the most recent ACIP schedules, but acknowledged that the absence of an ongoing review process means those schedules will grow stale.
The broader pattern extends well beyond vaccines. Kennedy’s HHS has moved aggressively to reshape the FDA’s advisory structure as well. Drug safety and efficacy panels — the committees that review clinical trial data and vote on whether new therapies should be approved — have seen membership shakeups and, in some cases, outright cancellations of scheduled meetings. Former FDA officials, speaking to multiple outlets, have described an atmosphere of uncertainty inside the agency, where career scientists are unsure whether their work will be reviewed by qualified peers or overridden by appointees with no relevant background.
The legal basis for the cuts rests on the Federal Advisory Committee Act, which gives agency heads significant discretion over the creation and termination of advisory bodies. Kennedy’s team has argued that many of the dissolved panels had outlived their statutory mandates or could be reconstituted in different forms if needed. Legal scholars have noted that while the terminations may be technically permissible, the scale and speed of the action are without precedent in the modern era of federal health governance.
“We’ve never seen anything like this,” said one former HHS official who served under both Republican and Democratic administrations, quoted by Ars Technica. “These committees were the connective tissue between the scientific community and the policy apparatus. Removing them doesn’t just change how decisions get made — it changes whether they get made at all.”
And that may be the point.
Kennedy has been transparent about his belief that the existing public health establishment is fundamentally broken. His book The Real Anthony Fauci laid out an extensive indictment of the NIH, FDA, and CDC, accusing them of systematic corruption and suppression of alternative treatments. His appointment as HHS secretary was itself a signal that the administration intended not to reform these institutions but to subordinate them to a different philosophy — one that privileges individual choice over population-level intervention, skepticism over consensus, and political accountability over technocratic independence.
Supporters see this as long overdue. They point to legitimate failures — the opioid crisis, the FDA’s approval of drugs later found to be dangerous, the CDC’s stumbling early response to COVID-19 — as evidence that expert panels didn’t prevent catastrophic mistakes and may have enabled them. The argument has political force. Trust in public health institutions has declined sharply since 2020, and Kennedy’s populist critique taps into real anger about perceived arrogance and opacity in the scientific establishment.
But critics counter that the solution to flawed expertise isn’t the elimination of expertise. It’s better expertise — more rigorous conflict-of-interest screening, more transparency, more diverse representation on panels. Dismantling the advisory infrastructure, they argue, doesn’t empower patients or improve accountability. It concentrates decision-making power in the hands of fewer people, with less scrutiny and less specialized knowledge.
The numbers are stark. Before Kennedy’s tenure, HHS maintained approximately 100 active advisory committees spanning its component agencies: the CDC, FDA, NIH, HRSA, SAMHSA, and others. Each committee operated under a charter specifying its scope, membership criteria, and reporting obligations. Members served fixed terms and were typically drawn from academia, clinical practice, and, yes, sometimes industry — with disclosure requirements designed to manage potential conflicts. The system wasn’t perfect. No system involving humans and money ever is. But it had a structural logic: bring the best available knowledge to bear on complex decisions, in a format that allowed for debate, dissent, and documentation.
Twenty-seven of those committees are gone. Others have been placed under review, their futures uncertain. The institutional knowledge represented by hundreds of former committee members — the people who understood the history of specific regulatory decisions, who could recall why a particular vaccine formulation was chosen or why a blood safety protocol was written the way it was — is dispersing. Some of those experts have already moved on. Others say they wouldn’t serve again even if asked, given the political environment.
So what fills the void?
In some cases, nothing. Decisions that previously went through a structured advisory process are now being made internally, by smaller groups of political appointees and career staff operating without the formal input mechanisms that advisory committees provided. In other cases, Kennedy’s team has signaled interest in creating new bodies more aligned with the secretary’s priorities — panels focused on what HHS has called “medical freedom” and “health sovereignty,” concepts that don’t map neatly onto the traditional framework of evidence-based public health.
The medical and scientific communities have responded with a mix of alarm and resignation. Major professional organizations — the AMA, the Infectious Diseases Society of America, the American Public Health Association — have issued formal objections. But their leverage is limited. Advisory committees exist at the pleasure of agency leadership, and the courts have historically been reluctant to second-guess executive branch decisions about internal organizational structure.
There’s a historical parallel worth considering. In the early 1980s, the Reagan administration made significant cuts to federal advisory bodies as part of a broader deregulatory agenda. But even then, the health-related committees were largely spared, on the bipartisan understanding that scientific advisory functions served a fundamentally different purpose than, say, a commerce department panel on trade policy. That distinction appears to have collapsed.
The implications extend internationally. The WHO and health agencies in allied nations have long looked to U.S. federal advisory committees — particularly ACIP and the FDA’s drug and vaccine panels — as reference points for their own decision-making. Several European health officials have privately expressed concern that the dissolution of these bodies will complicate coordination on pandemic preparedness, drug safety surveillance, and global immunization efforts. One senior official at a European medicines agency told reporters that the situation was “deeply troubling” and that contingency planning was underway to reduce reliance on U.S. regulatory signals.
For the American public, the effects may take time to become fully visible. Advisory committees operated largely out of public view, their work technical and unglamorous. Most people couldn’t name a single member of ACIP or describe what the Board of Scientific Counselors does. But the outputs of those committees — the vaccine schedules, the drug safety warnings, the dietary recommendations, the workplace exposure limits — touched nearly every aspect of daily life. Their absence won’t announce itself with a single dramatic failure. It will show up gradually, in slower responses to emerging threats, in less-informed regulatory decisions, in a growing gap between what the science says and what the government does.
Kennedy’s defenders will argue that this is precisely the disruption that was promised and that voters endorsed. That the old system served insiders, not the public. That fresh eyes and new approaches are needed. These are arguments that deserve to be engaged on their merits, not dismissed.
But the merits require specifics. Which committees were genuinely redundant? Which had documented conflicts of interest that compromised their recommendations? What alternative mechanisms will ensure that complex scientific questions receive adequate expert review before policy decisions are made? On these questions, the administration has offered rhetoric but little detail.
Twenty-seven percent of HHS advisory panels, dissolved. Hundreds of expert positions, eliminated. Decades of institutional practice, upended. The architecture of scientific advice that helped guide American public health policy through HIV, anthrax, H1N1, Ebola, Zika, and COVID-19 — diminished in ways that may prove very difficult to reverse. Whether this represents liberation from a captured bureaucracy or the dismantling of a public good will likely be debated for years. The consequences, however, won’t wait for the debate to conclude.
WebProNews is an iEntry Publication